ESMO Congress 2023 updates

LOTS of new ADCs, Immunotherapy in ER+ breast cancer, some cool stuff on highly sensitive analyses for ctDNA, more cool stuff on Epigenomic liquid biopsy profiling. Intronic variants, do they have any clinical relevance, or should we keep filtering them out (hint, no we should not). Also, where does the discussion on HRD stand?